# EDGAR Filing Document

**Accession Number:** 0001441252
**File Stem:** 0001104659-26-046231
**Filing Date:** 2026-4
**Character Count:** 11677
**Document Hash:** 257bd5cdb4958de2a1cbb3bad12ff694
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-046231.hdr.sgml**: 20260421

**ACCESSION NUMBER**: 0001104659-26-046231

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260421

**DATE AS OF CHANGE**: 20260421

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NEUROONE MEDICAL TECHNOLOGIES Corp
- **CENTRAL INDEX KEY:** 0001500198
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 270863354
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-87476
- **FILM NUMBER:** 26881020

**BUSINESS ADDRESS:**
- **STREET 1:** 7599 ANAGRAM DR
- **CITY:** EDEN PRAIRIE
- **STATE:** MN
- **ZIP:** 55344
- **BUSINESS PHONE:** (952) 426-1383

**MAIL ADDRESS:**
- **STREET 1:** 7599 ANAGRAM DR
- **CITY:** EDEN PRAIRIE
- **STATE:** MN
- **ZIP:** 55344

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Original Source Entertainment, Inc.
- **DATE OF NAME CHANGE:** 20100830
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Pratt Brian
- **CENTRAL INDEX KEY:** 0001441252

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G

**MAIL ADDRESS:**
- **STREET 1:** 5950 BERKSHIRE LANE, SUITE 800
- **CITY:** DALLAS
- **STATE:** TX
- **ZIP:** 75225

## Exhibit 99.1

**Exhibit 1**

**JOINT FILING AGREEMENT**

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to shares of common stock, par value $0.001 per share, of NeuroOne Medical Technologies Corporation, and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings.

In evidence thereof, the undersigned, being duly authorized, have executed this Joint Filing Agreement as of April 21, 2026.

---

| |
|:---|
| &nbsp;&nbsp;/s/ Brian Pratt |
| &nbsp;&nbsp;Brian Pratt |
| &nbsp;&nbsp;/s/ Barbara Pratt |
| &nbsp;&nbsp;Barbara Pratt |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**Issuer:** NeuroOne Medical Technologies Corporation

**Title of Class of Securities:** Common Stock

**CUSIP Number:** —

**Date of Event Which Requires Filing of this Statement:** 04/14/2026

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [x] Rule 13d-1(c)

- [ ] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>Brian Pratt | Names of Reporting Persons<br>Brian Pratt |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>X1 | Citizenship or Place of Organization<br>X1 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>627344.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>627344.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>627344.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>627344.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>7.4% | Percent of Class Represented by Amount in Row (9)<br>7.4% |
| 12. | Type of Reporting Person (See Instructions)<br>IN | Type of Reporting Person (See Instructions)<br>IN |

**Comment for Type of Reporting Person:** The amounts reported in boxes 6, 8, and 9 represent 627,344 shares of common stock, par value $0.001 per share ("Common Stock"), of NeuroOne Medical Technologies Corporation (the "Company"), held in a joint account with Brian Pratt's spouse.

The percentage in box 11 is based on 8,420,999 shares of Common Stock outstanding following a 1-for-6 reverse stock split of 50,525,995 shares of Common Stock outstanding as of February 13, 2026, as reported in the Company's Quarterly Report on Form 10-Q filed on February 17, 2026. The reverse stock split was effective as of April 15, 2026, as reported in the Company's Current Report on Form 8-K filed on April 14, 2026.

---

| 1. | Names of Reporting Persons<br>Barbara Pratt | Names of Reporting Persons<br>Barbara Pratt |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>X1 | Citizenship or Place of Organization<br>X1 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>627344.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>627344.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>627344.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>627344.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>7.4% | Percent of Class Represented by Amount in Row (9)<br>7.4% |
| 12. | Type of Reporting Person (See Instructions)<br>IN | Type of Reporting Person (See Instructions)<br>IN |

**Comment for Type of Reporting Person:** The amounts reported in boxes 6, 8, and 9 represent 627,344 shares of common stock, par value $0.001 per share ("Common Stock"), of NeuroOne Medical Technologies Corporation (the "Company"), held in a joint account with Barbara Pratt's spouse.

The percentage in box 11 is based on 8,420,999 shares of Common Stock outstanding following a 1-for-6 reverse stock split of 50,525,995 shares of Common Stock outstanding as of February 13, 2026, as reported in the Company's Quarterly Report on Form 10-Q filed on February 17, 2026. The reverse stock split was effective as of April 15, 2026, as reported in the Company's Current Report on Form 8-K filed on April 14, 2026.

---

**Item 1(a). Name of Issuer:**
NeuroOne Medical Technologies Corporation

**Item 1(b). Address of Issuer's Principal Executive Offices:**
7599 Anagram Drive, Eden Prairie, MN 55344

**Item 2(a). Name of Person Filing:**
Brian Pratt; and
Barbara Pratt

**Item 2(b). Address of Principal Business Office:**
The address of the principal business office of each Reporting Person is 5950 Berkshire Lane, Ste. 800, Dallas, Texas 75225.

**Item 2(c). Citizenship:**
Each Reporting Person is a citizen of the United States of America.

**Item 2(d). Title of Class of Securities:**
Common Stock

**Item 2(e). CUSIP Number:**
—

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

The information set forth on the cover page of this Schedule 13G is incorporated herein by reference.

**(b) Percent of class:**

The information set forth on the cover page of this Schedule 13G is incorporated herein by reference.

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

The information set forth on the cover page of this Schedule 13G is incorporated herein by reference.

**(ii) Shared power to vote or to direct the vote:**

The information set forth on the cover page of this Schedule 13G is incorporated herein by reference.

**(iii) Sole power to dispose or to direct the disposition of:**

The information set forth on the cover page of this Schedule 13G is incorporated herein by reference.

**(iv) Shared power to dispose or to direct the disposition of:**

The information set forth on the cover page of this Schedule 13G is incorporated herein by reference.

**Item 5. Ownership of Five Percent or Less of a Class.**

[x] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Brian Pratt**

**Date:** 04/21/2026

**By:** /s/ Brian Pratt

**Name & Title:** Brian Pratt

**Barbara Pratt**

**Date:** 04/21/2026

**By:** /s/ Barbara Pratt

**Name & Title:** Barbara Pratt